Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Dimethyl fumarate suppresses Theiler's murine encephalomyelitis virus - induced demyelinating disease by modifying Nrf2-Keap1 pathway.
Synaptic pathology: a shared mechanism in neurological disease.
Dimethyl fumarate-associated lymphopenia: Risk factors and clinical significance.
Imaging in Pediatric Demyelinating and Inflammatory Diseases of Brain- Part 2.
Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up.
Site-Specific PEGylation Enhances the Pharmacokinetic Properties and Antitumor Activity of Interferon Beta-1b.
Clinical and MRI predictors of response to interferon-beta and glatiramer acetate in relapsing-remitting multiple sclerosis patients.
Effects of fumaric acid esters on blood-brain barrier tight junction proteins.
More Than 15 Years of Experience with Intradetrusor OnabotulinumtoxinA Injections for Treating Refractory Neurogenic Detrusor Overactivity: Lessons to Be Learned.
Chemical and Biological Therapeutic Approaches to Neurological Disorders III
Berlex continues legal challenge to FDA over MS drug.
Knockdown of Lingo1b protein promotes myelination and oligodendrocyte differentiation in zebrafish.
Switch to natalizumab vs fingolimod in active relapsing-remitting multiple sclerosis.
Vision Disturbances in Multiple Sclerosis.
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis.
Mitoxantrone repression of astrocyte activation: Relevance to multiple sclerosis.
FTY720 impairs CD8 T-cell function independently of the sphingosine-1-phosphate pathway.
Gordon Research Conference on Myelin Biology and Pathobiology of Myelinating Glia
Maternal and perinatal outcomes in pregnancies with multiple sclerosis: a case-control study.
Treatment satisfaction in multiple sclerosis.
Interferon-beta(1b) treatment in neuromyelitis optica.
Rituximab (marketed as Rituxan), Information
The cytoskeleton as a novel therapeutic target for old neurodegenerative disorders.
Nanoparticle transport across the blood brain barrier.
Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS.

Pages